Lam Research Corporation (LRCX) financial statements: income statement, balance sheet and cash flow
Lam Research Corporation's income statement, balance sheet and cash flow statement as filed with the SEC (10-K and 10-Q), with the latest fiscal years and quarters. In its latest fiscal year (Jun 28, 2026 · FY), Lam Research Corporation reported revenue of $23.2B (+26.0% year on year) and net income of $7.3B (+35.6% year on year).
Income statement
Lam Research Corporation income statement, fiscal years
Line item
Jun 28, 2026 · FY
Jun 29, 2025 · FY
Jun 30, 2024 · FY
Jun 25, 2023 · FY
Revenue
$23.2B
$18.4B
$14.9B
$17.4B
Cost of goods sold
$11.5B
$9.5B
$7.8B
$9.6B
Restructuring charges, net - cost of goods sold
$0
$0
$43.4M
$78.2M
Total cost of goods sold
$11.5B
$9.5B
$7.9B
$9.7B
Gross margin
$11.7B
$9.0B
$7.1B
$7.8B
Research and development
$2.4B
$2.1B
$1.9B
$1.7B
Selling, general, and administrative
$1.1B
$981.7M
$868.2M
$832.8M
Restructuring charges, net - operating expenses
$0
$0
$18.2M
$42.1M
Total operating expenses
$3.5B
$3.1B
$2.8B
$2.6B
Operating income
$8.2B
$5.9B
$4.3B
$5.2B
Other income (expense), net
$62.7M
$57.2M
$96.3M
($65.7M)
Income before income taxes
$8.3B
$6.0B
$4.4B
$5.1B
Income tax expense
($997.1M)
($599.9M)
($532.5M)
($598.3M)
Net income
$7.3B
$5.4B
$3.8B
$4.5B
Basic (in dollars per share)
$5.79
$4.17
$29.13
$33.30
Diluted (in dollars per share)
$5.76
$4.15
$29.00
$33.21
Basic (in shares)
1.3B
1.3B
131.4M
135.5M
Diluted (in shares)
1.3B
1.3B
132.0M
135.8M
Lam Research Corporation income statement, quarters
Line item
Sep 27, 2026 · Q1
Mar 29, 2026 · Q3
Dec 28, 2025 · Q2
Sep 28, 2025 · Q1
Revenue
$8.2B
$5.8B
$5.3B
$5.3B
Cost of goods sold
$3.9B
$2.9B
$2.7B
$2.6B
Gross margin
$4.3B
$2.9B
$2.7B
$2.7B
Research and development
$666.4M
$583.2M
$573.3M
$576.4M
Selling, general, and administrative
$348.7M
$280.3M
$267.7M
$279.3M
Total operating expenses
$1.0B
$863.5M
$841.0M
$855.8M
Operating income
$3.3B
$2.0B
$1.8B
$1.8B
Other income (expense), net
$28.5M
($35.5M)
$26.4M
$30.1M
Income before income taxes
$3.3B
$2.0B
$1.8B
$1.9B
Income tax expense
($559.1M)
($186.1M)
($242.6M)
($290.5M)
Net income
$2.8B
$1.8B
$1.6B
$1.6B
Basic (in dollars per share)
$2.20
$1.46
$1.27
$1.24
Diluted (in dollars per share)
$2.19
$1.45
$1.26
$1.24
Basic (in shares)
1.3B
1.2B
1.3B
1.3B
Diluted (in shares)
1.3B
1.3B
1.3B
1.3B
Balance sheet
Lam Research Corporation balance sheet, fiscal years
Line item
Jun 28, 2026 · FY
Jun 29, 2025 · FY
Jun 30, 2024 · FY
Jun 25, 2023 · FY
Cash and cash equivalents
$5.6B
$6.4B
$5.8B
$5.3B
Accounts receivable, less allowance of $8,071 as of June 28, 2026 and $6,496 as of June 29, 2025
$5.3B
$3.4B
$2.5B
$2.8B
Inventories
$4.3B
$4.3B
$4.2B
$4.8B
Prepaid expenses and other current assets
$415.7M
$440.3M
$298.2M
$214.1M
Total current assets
$15.6B
$14.5B
$12.9B
$13.2B
Property and equipment, net
$3.0B
$2.4B
$2.2B
$1.9B
Goodwill and intangible assets, net
$1.9B
$1.8B
—
—
Other assets
$3.1B
$2.6B
$1.9B
$1.7B
Total assets
$23.5B
$21.3B
$18.7B
$18.8B
Trade accounts payable
$1.3B
$854.2M
$614.0M
$470.7M
Accrued expenses and other current liabilities
$2.4B
$2.4B
$1.8B
$2.0B
Deferred profit
$2.3B
$2.6B
$1.4B
$1.7B
Current portion of long-term debt and finance lease obligations
$4.1M
$754.3M
$504.8M
$8.4M
Total current liabilities
$5.9B
$6.6B
$4.3B
$4.2B
Long-term debt and finance lease obligations
$3.7B
$3.7B
$4.5B
$5.0B
Income taxes payable
$681.2M
$603.4M
$813.3M
$882.1M
Other long-term liabilities
$709.9M
$581.6M
$575.0M
$501.3M
Total liabilities
$11.1B
$11.5B
$10.2B
$10.6B
Preferred stock, at par value of $0.001 per share; authorized - 5,000 shares, none outstanding
$0.00
$0.00
$0.00
$0.00
Common stock, at par value of $0.001 per share; authorized 4,000,000 shares as of June 28, 2026 and June 29, 2025; issued and outstanding 1,251,278 shares as of June 28, 2026, and 1,268,740 shares as of June 29, 2025
$1251000.00
$1268000.00
$130000.00
$133000.00
Additional paid-in capital
$9.2B
$8.7B
$8.2B
$7.8B
Treasury stock, at cost, 1,710,109 shares as of June 28, 2026, and 1,687,582 shares as of June 29, 2025
-31.6B
-27.8B
-24.4B
-21.5B
Accumulated other comprehensive loss
($127.1M)
($62.4M)
($130.4M)
($100.7M)
Retained earnings
$35.0B
$29.0B
$24.8B
$22.0B
Total stockholders’ equity
$12.5B
$9.9B
$8.5B
$8.2B
Total liabilities and stockholders’ equity
$23.5B
$21.3B
$18.7B
$18.8B
Lam Research Corporation balance sheet, quarters
Line item
Sep 27, 2026
Mar 29, 2026
Dec 28, 2025
Sep 28, 2025
Cash and cash equivalents
$7.4B
$4.8B
$6.2B
$6.7B
Accounts receivable, less allowance of $8,358 as of September 27, 2026, and $8,071 as of June 28, 2026
$5.7B
$4.1B
$3.5B
$3.6B
Inventories
$4.6B
$4.0B
$4.0B
$4.1B
Prepaid expenses and other current assets
$477.8M
$413.1M
$307.9M
$385.6M
Total current assets
$18.1B
$13.3B
$14.0B
$14.8B
Property and equipment, net
$3.1B
$2.9B
$2.7B
$2.5B
Goodwill and intangible assets, net
$1.9B
$1.9B
$1.9B
$1.8B
Other assets
$3.2B
$2.8B
$2.8B
$2.8B
Total assets
$26.4B
$20.8B
$21.4B
$21.9B
Trade accounts payable
$1.6B
$1.1B
$1.0B
$863.2M
Accrued expenses and other current liabilities
$3.3B
$2.1B
$2.3B
$2.4B
Deferred profit
$2.4B
$2.1B
$2.2B
$2.6B
Current portion of long-term debt and finance lease obligations
$3.5M
$4.1M
$754.0M
$754.4M
Total current liabilities
$7.3B
$5.2B
$6.2B
$6.7B
Long-term debt and finance lease obligations
$3.7B
$3.7B
$3.7B
$3.7B
Income taxes payable
$684.3M
$621.6M
$667.6M
$646.0M
Other long-term liabilities
$715.9M
$612.8M
$635.2M
$623.9M
Total liabilities
$12.4B
$10.2B
$11.2B
$11.7B
Preferred stock, at par value of $0.001 per share; authorized, 5,000 shares, none outstanding
$0.00
$0.00
$0.00
$0.00
Common stock, at par value of $0.001 per share; authorized, 4,000,000 shares as of September 27, 2026 and June 28, 2026; issued and outstanding, 1,249,145 shares as of September 27, 2026, and 1,251,278 shares as of June 28, 2026
$1249000.00
$1251000.00
$1251000.00
$1258000.00
Additional paid-in capital
$9.4B
$9.1B
$8.9B
$8.8B
Treasury stock, at cost; 1,712,490 shares as of September 27, 2026, and 1,710,109 shares as of June 28, 2026
-32.6B
-31.3B
-30.2B
-28.8B
Accumulated other comprehensive loss
($127.3M)
($121.4M)
($98.7M)
($73.6M)
Retained earnings
$37.3B
$33.0B
$31.5B
$30.2B
Total stockholders’ equity
$13.9B
$10.6B
$10.1B
$10.2B
Total liabilities and stockholders’ equity
$26.4B
$20.8B
$21.4B
$21.9B
Cash flow statement
Lam Research Corporation cash flow statement, fiscal years
Line item
Jun 28, 2026 · FY
Jun 29, 2025 · FY
Jun 30, 2024 · FY
Jun 25, 2023 · FY
Net income
$7.3B
$5.4B
$3.8B
$4.5B
Depreciation and amortization
$441.5M
$386.3M
$359.7M
$342.4M
Deferred income taxes
($289.1M)
($363.2M)
($199.0M)
($172.1M)
Equity-based compensation expense
$386.4M
$343.4M
$293.1M
$286.6M
Other, net
($32.7M)
$6.8M
$10.2M
$52.3M
Accounts receivable, net of allowance
($2.0B)
($858.7M)
$303.4M
$1.5B
Inventories
($93.9M)
($180.7M)
$528.7M
($962.0M)
Prepaid expenses and other assets
$50.2M
($206.7M)
($15.5M)
$136.0M
Trade accounts payable
$417.5M
$212.0M
$125.9M
($522.2M)
Deferred profit
($286.4M)
$1.1B
($277.4M)
$163.5M
Accrued expenses and other liabilities
($39.3M)
$328.3M
($304.7M)
($108.8M)
Net cash provided by operating activities
$5.9B
$6.2B
$4.7B
$5.2B
Capital expenditures and intangible assets
($966.4M)
($759.2M)
($396.7M)
($501.6M)
Proceeds from maturities of available-for-sale securities
$0
$0
$34.3M
$91.3M
Proceeds from sales of available-for-sale securities
$0
$0
$3.4M
$6.8M
Other, net
$44.3M
$51.1M
($11.7M)
($11.2M)
Net cash used for investing activities
($922.2M)
($708.1M)
($370.6M)
($534.6M)
Principal payments on long-term debt and finance lease obligations and payments for debt issuance costs
($755.4M)
($507.5M)
($256.1M)
($23.2M)
Treasury stock purchases
($3.9B)
($3.4B)
($2.8B)
($2.0B)
Dividends paid
($1.3B)
($1.1B)
($1.0B)
($907.9M)
Reissuances of treasury stock related to employee stock purchase plan
$156.0M
$140.1M
$120.0M
$109.9M
Proceeds from issuance of common stock
$17.4M
$2.5M
$15.6M
$11.1M
Other, net
($13.8M)
$143.0K
($13.5M)
($3.6M)
Net cash used for financing activities
($5.7B)
($4.9B)
($4.0B)
($2.8B)
Effect of exchange rate changes on cash, cash equivalents and restricted cash
($27.4M)
$28.3M
($22.4M)
$128.0K
Net change in cash, cash equivalents and restricted cash
($809.7M)
$556.9M
$263.4M
$1.8B
Cash, cash equivalents and restricted cash at beginning of year
$6.4B
$5.9B
$5.6B
$3.8B
Cash, cash equivalents and restricted cash at end of year
$5.6B
$6.4B
$5.9B
$5.6B
Accrued payables for stock repurchases, including applicable excise tax
$34.3M
$38.5M
$51.5M
$45.5M
Accrued payables for capital expenditures
$119.6M
$80.8M
$60.8M
$31.9M
Dividends payable
$325.4M
$292.0M
$260.9M
$231.3M
Transfers of finished goods inventory to property and equipment
$125.7M
$90.9M
$71.3M
$76.9M
Cash payments for interest
$150.1M
$172.4M
$173.1M
$174.7M
Cash and cash equivalents
$5.6B
$6.4B
$5.8B
$5.3B
Restricted cash and cash equivalents
$18.8M
$17.0M
$2.9M
$250.3M
Total cash, cash equivalents, and restricted cash
$5.6B
$6.4B
$5.9B
$5.6B
Lam Research Corporation cash flow statement, quarters
Line item
Sep 27, 2026 · Q1
Mar 29, 2026 · YTD
Dec 28, 2025 · YTD
Sep 28, 2025 · Q1
Net income
$2.8B
$5.0B
$3.2B
$1.6B
Depreciation and amortization
$122.1M
$321.9M
$205.6M
$101.6M
Deferred income taxes
($55.3M)
($113.3M)
($93.8M)
($62.9M)
Equity-based compensation expense
$114.7M
$282.4M
$185.8M
$97.2M
Other, net
$27.6M
($24.7M)
($21.9M)
($1.9M)
Changes in operating assets and liabilities
$535.4M
($1.1B)
($179.3M)
$76.2M
Net cash provided by operating activities
$3.5B
$4.4B
$3.3B
$1.8B
Capital expenditures and intangible assets
($257.7M)
($777.6M)
($446.0M)
($185.1M)
Other, net
($9.3M)
($807.0K)
$2.2M
($927.0K)
Net cash used for investing activities
($267.0M)
($778.4M)
($443.8M)
($186.0M)
Principal payments on debt, including finance lease obligations and payments for debt issuance costs
($34.5M)
($754.1M)
($2.9M)
($1.4M)
Treasury stock purchases, including excise tax payments
($1.0B)
($3.6B)
($2.4B)
($975.8M)
Dividends paid
($325.4M)
($945.3M)
($619.5M)
($292.0M)
Proceeds from issuance of common stock, net of issuance costs
$4.3M
$13.0M
$3.9M
$0
Other, net
($1.8M)
($13.5M)
($13.6M)
($12.4M)
Net cash used for financing activities
($1.4B)
($5.2B)
($3.0B)
($1.3B)
Effect of exchange rate changes on cash, cash equivalents, and restricted cash
$4.7M
($25.4M)
($20.4M)
($7.1M)
Net change in cash, cash equivalents, and restricted cash
$1.9B
($1.6B)
($212.1M)
$304.2M
Cash, cash equivalents, and restricted cash at beginning of period
$5.6B
$6.4B
$6.4B
$6.4B
Cash, cash equivalents, and restricted cash at end of period
$7.5B
$4.8B
$6.2B
$6.7B
Accrued payables for stock repurchases, including applicable excise tax
$31.5M
$23.7M
$42.6M
$58.8M
Accrued payables for capital expenditures
$142.0M
$84.7M
$142.6M
$95.7M
Dividends payable
$412.2M
$325.3M
$325.8M
$327.5M
Transfers of finished goods inventory to property and equipment